July 30 (Reuters) - Appili Therapeutics Inc APLI.V :
* APPILI PREPARES CANADIAN LONG-TERM CARE FACILITIES TO ENROLL PARTICIPANTS IN A CLINICAL TRIAL EVALUATING FAVIPIRAVIR AS AN OUTBREAK CONTROL AGENT AGAINST COVID-19
* APPILI THERAPEUTICS INC - TRIAL IS EXPECTED TO ULTIMATELY ENROLL ABOUT 760 PARTICIPANTS AT 16 LTC FACILITIES